Mira Pharmaceuticals Adds New Director, Dr. Jianjun Li
Ticker: MIRA · Form: 8-K · Filed: May 29, 2024 · CIK: 1904286
| Field | Detail |
|---|---|
| Company | Mira Pharmaceuticals, Inc. (MIRA) |
| Form Type | 8-K |
| Filed Date | May 29, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $0.3 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-composition, executive-appointments, governance
TL;DR
Mira Pharma adds pharma vet Dr. Li to board & comp committee.
AI Summary
Mira Pharmaceuticals, Inc. announced on May 29, 2024, the election of Dr. Jianjun "James" Li as a new director and the appointment of Dr. Li as the Chair of the Compensation Committee, effective May 28, 2024. Dr. Li brings extensive experience in the pharmaceutical industry, having previously held leadership roles at major companies.
Why It Matters
The addition of an experienced director like Dr. Li could signal a strategic shift or enhanced focus on the company's compensation and governance structures, potentially impacting future executive decisions and shareholder value.
Risk Assessment
Risk Level: low — This filing is a routine corporate governance update regarding board composition and committee appointments, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Mira Pharmaceuticals, Inc. (company) — Registrant
- Jianjun "James" Li (person) — Newly elected director and Chair of the Compensation Committee
- May 29, 2024 (date) — Date of report
- May 28, 2024 (date) — Effective date of director election and committee appointment
FAQ
What specific experience does Dr. Jianjun Li bring to Mira Pharmaceuticals?
The filing states Dr. Li brings extensive experience in the pharmaceutical industry, though specific details of his prior roles are not elaborated upon in this particular filing.
What is the effective date of Dr. Li's appointment?
Dr. Li's election as a director and appointment to the Compensation Committee were effective May 28, 2024.
What is Dr. Li's role on the Compensation Committee?
Dr. Li has been appointed as the Chair of the Compensation Committee.
What other items are reported in this 8-K filing?
This 8-K filing also covers the departure of directors or certain officers and the election of directors, in addition to the appointment of certain officers and compensatory arrangements.
Where is Mira Pharmaceuticals, Inc. headquartered?
Mira Pharmaceuticals, Inc. has its principal executive offices at 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida.
Filing Stats: 906 words · 4 min read · ~3 pages · Grade level 14.1 · Accepted 2024-05-29 08:30:38
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MIRA The Nasdaq
- $0.3 million — v's annual base salary was increased to $0.3 million per annum effective as of June 1, 2024,
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-24-021731.txt ( ) — 211KB
- mira-20240529.xsd (EX-101.SCH) — 3KB
- mira-20240529_lab.xml (EX-101.LAB) — 33KB
- mira-20240529_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIRA PHARMACEUTICALS, INC. Date: May 29, 2024 By: /s/ Michelle Yanez Michelle Yanez Chief Financial Officer